Bard Associates Inc Neogenomics Inc Transaction History
Bard Associates Inc
- $250 Million
- Q4 2024
A detailed history of Bard Associates Inc transactions in Neogenomics Inc stock. As of the latest transaction made, Bard Associates Inc holds 47,405 shares of NEO stock, worth $639,019. This represents 0.31% of its overall portfolio holdings.
Number of Shares
47,405
Previous 47,605
0.42%
Holding current value
$639,019
Previous $702,000
11.25%
% of portfolio
0.31%
Previous 0.26%
Shares
21 transactions
Others Institutions Holding NEO
# of Institutions
291Shares Held
124MCall Options Held
698KPut Options Held
116K-
Black Rock Inc. New York, NY19.7MShares$265 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.2MShares$192 Million0.0% of portfolio
-
Brown Advisory Inc6.89MShares$92.9 Million0.13% of portfolio
-
Janus Henderson Group PLC London, X06.6MShares$89 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.54MShares$88.2 Million0.06% of portfolio
About NEOGENOMICS INC
- Ticker NEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 125,796,000
- Market Cap $1.7B
- Description
- NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytoge...